rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We develop a genotype-based strategy that identifies CK2 as a promising co-target in KRAS(G12C) mutant NSCLC by using available pharmacogenomics gene expression datasets.
|
31668570 |
2019 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
|
30327306 |
2019 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
|
28407465 |
2017 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS G12C, the most common RAS mutation found in non-small-cell lung cancer, has been the subject of multiple recent covalent small-molecule inhibitor campaigns including efforts directed at the guanine nucleotide pocket and separate work focused on an inducible pocket adjacent to the switch motifs.
|
28781083 |
2017 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Isogenic NSCLC cell clones expressing wild-type (WT) and mutated (G12C) KRAS were used to determine the response to BEZ235 and BKM120.
|
27283493 |
2016 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Recently, G12C KRAS mutation in isogenic NSCLC cell line has been shown to be a key player in promoting metabolic rewiring mainly through the regulation of glutamine metabolism to fuel growth and proliferation.
|
27329432 |
2016 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The present studies demonstrate that silencing MUC1-C in A549/KRAS(G12S) and H460/KRAS(Q61H) NSCLC cells is associated with downregulation of AKT signaling and inhibition of growth.
|
25245423 |
2014 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Low frequency KRAS active (G12R) and EGFR kinase domain mutations (G719A) were identified in one NSCLC patient.
|
24200637 |
2014 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
In NSCLC GLY12Cys mutations, resulting from a codon 12 GGT>TGT substitution, were observed in 44% compared to 10% for CRC.
|
24331409 |
2014 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
|
23313110 |
2013 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.
|
22617245 |
2012 |
rs121913530
|
|
Non-Small Cell Lung Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
NSCLC cell lines with mutant KRas-Gly12Asp had activated phosphatidylinositol 3-kinase (PI-3-K) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling, whereas those with mutant KRas-Gly12Cys or mutant KRas-Gly12Val had activated Ral signaling and decreased growth factor-dependent Akt activation.
|
22247021 |
2012 |